Investigation Report on China Enoxaparin Sodium Market, 2009-2018

DUBLIN, Mar. 28, 2014 /PRNewswire/ --

Research and Markets

(

http://www.researchandmarkets.com/research/xvt3hx/investigation

) has announced the addition of the

"Investigation Report on China Enoxaparin Sodium Market, 2009-2018"

report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. It can result in anoxia, the complete deprivation of oxygen and infarction, and even tissue death. Twelve million people worldwide are killed every year by cardiovascular and cerebrovascular diseases such as cerebral thrombosis, cerebral infarction, myocardial infarction, coronary heart disease and arteriosclerosis. It equals to nearly one-fourth of global death toll. Incidence of cardiovascular diseases keeps rising in China. The number of cardiovascular diseases patients in China now is estimated to be 290 million with 2 patients among 10 adults. It is estimated that about 3.5 million people die of cardiovascular diseases every year in China. This number has topped all diseases and takes up 40% of total death toll.

Heparin drugs are widely used in hemodialysis and various surgical operations. Because low-molecular-weight heparin preparation is more widely used in clinical practice than unfractionated heparin preparation, the later is gradually being replaced by the former. Low-molecular-weight heparin preparation took up over 85% of the global heparin market from 2005 to 2010. Enoxaparin sodium is an important variety of low-molecular-weight heparin preparations, which is originally developed by Aventis (later merged with Sanofi). It was approved to the market in 1993 with the trade name ""Lovenox"". The active ingredient of the medication is a natural derivative of certain type of sugar molecule. Enoxaparin sodium injection produced by Sanofi was approved to the U.S. market in October 2004 by the FDA. It entered Chinese market early 2005.

Enoxaparin sodium can not only prevent DVT (deep vein thrombosis) and pulmonary embolism but also treat venous thrombosis. It can prevent thrombus in extracorporeal circulation during hemodialysis, and treat unstable angina and non-Q-wave myocardial infarction. Enoxaparin sodium generic drugs produced by Sandoz and Amphastar Pharm have gone on the market in succession since 2010, leading to a dramatic sales drop of similar products produced by Sanofi. The downstream market is thus reorganized. Global sales revenue of Lovenox in 2012 is approximately USD 2.5 billion, which decreased 10.3% YOY.

Key Topics Covered:

1 Relevant Concepts of Enoxaparin Sodium

2 Market Overview of Enoxaparin Sodium in China

3 Investigation on Sales Value of Enoxaparin Sodium in China, 2009-2013

4 Investigation on Market Share of Major Enoxaparin Sodium Manufacturers in China, 2009-2013

5 Investigation on Market Size of Enoxaparin Sodium by Dosage Form in China, 2009-2013

6 Reference Price of Enoxaparin Sodium Produced by Different Enterprises in China Hospital Market, 2014

7 Analysis on Major Enoxaparin Sodium Manufacturers in China, 2014

8 Prospect of China Enoxaparin Sodium Market, 2014-2018

Companies Mentioned:

• Sanofi
• Sanofi Winthrop Industrie S.A.
• Hangzhou Sanofi-Aventis Minsheng Pharmaceutical Co., Ltd.
• Hangzhou Jiuyuan Gene Engineering Co., Ltd.

For more information visit http://www.researchandmarkets.com/research/xvt3hx/investigation

Media Contact:

Laura Wood , +353-1-481-1716, [email protected]

SOURCE Research and Markets